SCHEMBL20765376

SCHEMBL20765376

CN(C)S(=O)(=O)c1ccc(Br)c(C(F)(F)F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.55
ESR1 P03372 1/20 0.44
ALDH1A1 P00352 3/20 0.41
HTT P42858 2/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TRPV4 Q9HBA0 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
KIF11 P52732 3/20 0.40
PKM P14618 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
VCAM1 P19320 1/20 0.40
POLB P06746 1/20 0.40
ABCC9 O60706 1/20 0.38
ABCC8 Q09428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30288807 1.00 MAPT (0.55) MAPTESR1ALDH1A1HTTLMNA
SCHEMBL19145383 0.81 L3MBTL1 (0.44) MAPTALDH1A1HTTLMNASMN1; SMN2
SCHEMBL847830 0.81 KMT2A (0.50) MAPTESR1ALDH1A1HDAC4HDAC6
SCHEMBL14478168 0.81 KIF11 (0.50) MAPTESR1HTTLMNASMN1; SMN2
SCHEMBL28450717 0.80 KIF11 (0.41) MAPTESR1HTTLMNASMN1; SMN2
SCHEMBL29913597 0.79 KIF11 (0.51) KIF11
SCHEMBL1541448 0.79 KIF11 (0.51) KIF11
SCHEMBL19117614 0.78 RORC (0.44) MAPTALDH1A1HTTLMNASMN1; SMN2
SCHEMBL8490622 0.78 LMNA (0.48) HTTLMNASMN1; SMN2TRPV4KDM4E
SCHEMBL1459011 0.78 TRPV4 (0.42) MAPTESR1ALDH1A1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303573-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives Grünenthal GmbH (DE) 2023-09-28 US disclosed
US-20230234949-A1 MORPHOLINYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2023-07-27 US disclosed
US-11560374-B2 Morpholinylpyridone compounds SPRINT BIOSCIENCE AB (SE) 2023-01-24 US disclosed
EP-4056569-A1 MORPHOLINYLPYRIDONE COMPOUNDS Sprint Bioscience AB (SE) 2022-09-14 EP disclosed
EP-3672962-B1 MORPHOLINYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2022-01-26 EP disclosed
US-20200361922-A1 MORPHOLINYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2020-11-19 US disclosed
EP-3672962-A1 MORPHOLINYLPYRIDONE COMPOUNDS Sprint Bioscience AB (SE) 2020-07-01 EP disclosed
WO-2019038390-A1 MORPHOLINYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2019-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11560374-B2 Morpholinylpyridone compounds MAP1B, RRP12, MYT1 MAPT 70/4885ESR1 3605/4885ALDH1A1 1584/4885
US-20200361922-A1 MORPHOLINYLPYRIDONE COMPOUNDS MAP1B, RRP12, MYT1 MAPT 70/4885ESR1 3605/4885ALDH1A1 1584/4885
US-20230234949-A1 MORPHOLINYLPYRIDONE COMPOUNDS MAP1B, RRP12, MYT1 MAPT 60/4885ESR1 3531/4885ALDH1A1 1728/4885
US-20230303573-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives OPRK1, OPRD1, OPRL1 MAPT 3629/4885ESR1 1206/4885ALDH1A1 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.